Clarius Ultrasound Reports: Users Surpass 1 Million High-Definition Ultrasound Exams

March 3, 2021

Clarius, five years after later, after Clarius introduced its first-generation wireless, handheld ultrasound systems in 2016, today the company offers ten ultrasound scanner options to meet the requirements of multiple medical specialties.

Today, Clarius has recorded more than a million ultrasound exams by its users on its free Clarius Cloud exam management system.

Clarius has recorded more than a million ultrasound exams by its users on its free Clarius Cloud exam management system.

“When our team saw the real-time counter on the Clarius Cloud tick to over a million ultrasound exams, we felt like we took a big step forward in our mission to enable more clinicians to use ultrasound imaging to improve patient care,” said Clarius CEO Laurent Pelissier. “Last year we introduced our second-generation ultrasound scanners, which we now sell in 95 countries worldwide. We’re proud to see ultrasound adoption is growing across the medical spectrum with users who span across more than 40 specialties.”

While there are now several vendors in the app-based ultrasound market, Clarius established itself as a leader by delivering high-resolution imaging that rivals high-performance laptop systems for a fraction of the cost, combined with advanced Artificial Intelligence and Cloud capabilities.

According to Dr. Oron Frenkel, an emergency physician who is dedicated to expanding the use of point-of-care (POCUS) ultrasound, high-definition image quality bolsters confidence in making clinical decisions, especially for novice users.

“When physicians don’t feel confident about what they’re seeing, they don’t take the proper actions to save a patient time or sometimes even a life,” said Dr. Frenkel, Chairman of the Clarius Medical Advisory Board. “Good image quality lends itself to improved confidence at the point-of-care, which enables the technology to really spread into wider realms and empower novice users to feel more confident in their early skills of diagnostic testing.”

Clarius ultrasound scanners operate with an app on most iOS and Android smart devices. The handheld scanners are most often used for musculoskeletal exams, urgent care, obstetrics, and veterinary medicine. Growing applications include plastic surgery and cosmetic dermatology procedures to improve procedural safety.

Dr. Marc Salzman was one of the world’s first plastic surgeons to use Clarius handheld ultrasound.

“Ultrasound used to be intimidating to learn and expensive to buy,” explains Dr. Salzman. “Users had to learn to adjust complicated knobs and buttons in addition to recognizing anatomy. The Clarius software is intuitive and you just tap, pinch, and swipe the touch screen to run the system. If you have a practice that’s anything like mine, you’ll use ultrasound every day.”

For physicians new to ultrasound, Clarius actively promotes the adoption and use of ultrasound through education. Last week the company introduced Clarius Classroom, featuring brief video tutorials and pathology interpretation by expert ultrasound users. The company also offers live monthly webinars on ultrasound education that are then offered on-demand.

“Medical practitioners have always been front and center to those of us who work at Clarius. Most of our customers are medical practitioners who are experts in their field, many of them among the first in their medical specialty to adopt point-of-care ultrasound,” said Clarius CEO Laurent Pelissier. “We consider it a privilege to support them with ultrasound imaging they trust to improve safety, diagnosis, treatment and ultimately deliver better patient care. We thank them for being part of the Clarius community! Today, we celebrate one million scans together.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy